GlaxoSmithKline plc (ADR)  

(Public, NYSE:GSK)   Watch this stock  
52.47
0.00 (0.00%)
Pre-market: 52.25 -0.22 (-0.42%)
Jun 19, 8:39AM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week 41.68 - 54.00
Open     -
Vol / Avg. 300.00/2.62M
Mkt cap 128.80B
P/E 20.03
Div/yield 0.55/4.47
EPS 2.62
Shares 2.45B
Beta 0.64
Inst. own 11%
Jun 12, 2013
GlaxoSmithKline Pharmaceuticals Ltd at Goldman Sachs Healthcare Conference
Jun 3, 2013
Morphosys AG Signs Global License Agreement with GlaxoSmithKline for Anti-Inflammatory Program MOR103 Conference Call
May 29, 2013
GlaxoSmithKline at Deutsche Bank dbAccess Health Care Conference
May 21, 2013
GlaxoSmithKline American Thoracic Society Conference Call
Apr 24, 2013
Q1 2013 GlaxoSmithKline PLC Earnings Conference Call
Apr 23, 2013
GlaxoSmithKline at Biotechnology Industry Organization (BIO) International Convention
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 15.90% 17.95%
Operating margin 24.42% 27.97%
EBITD margin - 35.06%
Return on average assets 9.78% 11.49%
Return on average equity 61.70% 65.96%
Employees 99,488 -
Carbon Disclosure Rating - 90/100

Address

C8 Gsk House, 980 Great West Road
BRENTFORD, ENG TW8 9GS
United Kingdom - Map
+44-20-80475000 (Phone)
+44-20-80477807 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK�s principal pharmaceutical products include medicines in therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. On January 30, 2013, GSK acquired additional 29.3% interest in GlaxoSmithKline Consumer Healthcare Ltd. In May 2013, GlaxoSmithKline PLC acquired Okairos AG.

Officers and directors

Andrew Philip Witty Chief Executive Officer, Executive Director
Age: 48
Bio & Compensation  - Reuters
Simon Dingemans Chief Financial Officer, Executive Director
Age: 49
Bio & Compensation  - Reuters
Moncef Slaoui Chairman - Research & Development, Executive Director
Age: 53
Bio & Compensation  - Reuters
Deirdre P. Connelly President - North American Pharmaceuticals
Age: 52
Bio & Compensation  - Reuters
Roger Connor President - Global Manufacturing & Supply
Bio & Compensation  - Reuters
Marc Dunoyer Chairman - GSK Japan, Global Head - GSK Rare Diseases
Portrait. Bio & Compensation  - Reuters
Shah Abbas Hussain President - Europe & EMAP
Age: 47
Bio & Compensation  - Reuters
Patrick Vallance President - Pharmaceuticals R&D
Bio & Compensation  - Reuters
Emma Walmsley President - Consumer Healthcare Worldwide
Bio & Compensation  - Reuters
Christophe Weber President - Vaccines
Bio & Compensation  - Reuters